Alnylam to Webcast Presentation at 2013 Bank of America Merrill Lynch Health Care Conference

  Alnylam to Webcast Presentation at 2013 Bank of America Merrill Lynch Health
  Care Conference

Bank of America Merrill Lynch 2013 Healthcare Conference

Business Wire

CAMBRIDGE, Mass. -- May 08, 2013

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, today announced that management will present a company overview at
the 2013 Bank of America Merrill Lynch Health Care Conference on Thursday, May
16, 2013 at 8:40 a.m. PT (11:40 a.m. ET) at Encore at the Wynn in Las Vegas.

A live audio webcast of the presentation will be available on the News &
Investors section of the company’s website, A replay of the
presentation will be available on the Alnylam website within 48 hours after
the event.

About Alnylam Pharmaceuticals

Alnylam is a biopharmaceutical company developing novel therapeutics based on
RNA interference, or RNAi. The company is leading the translation of RNAi as a
new class of innovative medicines with a core focus on RNAi therapeutics for
the treatment of genetically defined diseases, including ALN-TTR for the
treatment of transthyretin-mediated amyloidosis (ATTR), ALN-AT3 for the
treatment of hemophilia and rare bleeding disorders (RBD), ALN-AS1 for the
treatment of acute intermittent porphyria, ALN-PCS for the treatment of
hypercholesterolemia, and ALN-TMP for the treatment of beta-thalassemia and
iron-overload disorders. As part of its “Alnylam 5x15^TM” strategy, the
company expects to have five RNAi therapeutic products for genetically defined
diseases in clinical development, including programs in advanced stages, on
its own or with a partner by the end of 2015. Alnylam has additional partnered
programs in clinical or development stages, including ALN-RSV01 for the
treatment of respiratory syncytial virus (RSV) infection and ALN-VSP for the
treatment of liver cancers. The company’s leadership position on RNAi
therapeutics and intellectual property have enabled it to form major alliances
with leading companies including Merck, Medtronic, Novartis, Biogen Idec,
Roche, Takeda, Kyowa Hakko Kirin, Cubist, Ascletis, Monsanto, Genzyme, and The
Medicines Company. In addition, Alnylam holds an equity position in Regulus
Therapeutics Inc., a company focused on discovery, development, and
commercialization of microRNA therapeutics. Alnylam has also formed Alnylam
Biotherapeutics, a division of the company focused on the development of RNAi
technologies for applications in biologics manufacturing, including
recombinant proteins and monoclonal antibodies. Alnylam’s VaxiRNA™ platform
applies RNAi technology to improve the manufacturing processes for vaccines;
GlaxoSmithKline is a collaborator in this effort. Alnylam scientists and
collaborators have published their research on RNAi therapeutics in over 100
peer-reviewed papers, including many in the world’s top scientific journals
such as Nature, Nature Medicine, Nature Biotechnology, and Cell. Founded in
2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more
information, please visit


Alnylam Pharmaceuticals, Inc.
Cynthia Clayton, 617-551-8207
Vice President, Investor Relations and Corporate Communications
Amanda Sellers (Media), 202-955-6222 x2597
Press spacebar to pause and continue. Press esc to stop.